CD274 and neoplasm: Beyond underscoring the value of personalized treatment in the intricate setting of coexisting high PD-L1 expression and <i>MET</i>-driven mutations, this case hints at a novel strategy: sequential <i>MET</i> inhibitor treatment restore sensitivity to immunotherapy responses by modifying the tumor microenvironment.